|Day Low/High||189.20 / 191.39|
|52 Wk Low/High||142.81 / 237.41|
Net income amounts to EUR 491 million supported by increase in underlying earnings Underlying earnings increase by 2% to EUR 1,064 million, or 10% on constant currencies driven by expense savings, a higher investment margin in the Netherlands, performance...
Aegon has agreed to sell its businesses in Czech Republic and Slovakia for EUR 155 million to NN Group.
The Dow Jones Industrial Average declined by 125 points on Monday.
The first is the ISE Equity Ratio which chimed in at 213%, its first reading over 200% since January 26.
- Five New Board Members Added in Last 18 Months -
Reinforces both Allergan's and Editas' continued commitment to developing innovative treatments for unmet needs in eye care
This downward action in the small biotech sector tends to happen often in the 'dog days' of summer.
Jim Cramer weighs in on Procter & Gamble, Six Flags, Western Digital, Allergan, Principal Financial Group.
Jim Cramer says somebody panicked, and their departure left behind a mess in the tech sector. But that spells a buying opportunity.
These names are showing technical characteristics of either bullish or bearish reversal patterns over the past week.
We are looking at today's rotation as an opportunity to pick up a high-quality name at a discount.
-- Dividend to be Paid on September 17, 2018 --
Botox maker Allergan's CEO is pushing back against activist investors and may get help from the company's latest earnings report.
Recent moves in industrial stocks demonstrate the importance of buying hated stock/groups when your conviction is high.
The drug giant beat analyst expectations for Q2 and issued positive guidance for the rest of the year.
Micron Technology, Intel and Lam Research are good buys on this heat in semiconductors.
U.S. stock futures are mixed as investors react with caution to a broadly worded trade truce between the European Union and the United States; Facebook tanks as the social media giant points to slower growth; AMD swings to a profit; Qualcomm scraps deal for NXP.
- Q2 2018 GAAP Loss Per Share of $1.39; Non-GAAP Performance Net Income Per Share of $4.42 -
- New Molecule Recognized as a Potentially Innovative Treatment for MDD, a Serious Condition with Persistent Unmet Need -
Abicipar, the first and only anti-VEGF to maintain stable vision in greater than 91 percent of patients on a fixed 12-week regimen, achieved the primary endpoint of non-inferiority to monthly ranibizumab at week 52
Jim Cramer uses PepsiCo's earnings, which crushed analysts' expectations, to illustrate why investors need to do their own homework to find real winners.
- New Artificial Tear Improves Clarity of Vision, Protects The Eye's Surface And Treats The Signs And Symptoms Of Dry Eye -
Aegon today announces that it has signed an agreement to expand its successful partnership with Banco Santander in Spain.
- Award-winning Chronic Migraine epidemiology study (CaMEO) and 17 additional presentations showcase Allergan innovation and leadership in research for migraine treatment and prevention -
DUBLIN, June 26, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that it intends to release second quarter 2018 financial results on Thursday, July 26, 2018, prior to the open of U.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.